Table 6.
Factors associated with the presence of severe fatigue at the 3-month evaluation of COVID-19 patients
| Variable | Patients with severe fatigue in the third month |
Patients without severe fatigue in the third month |
p a) | ||
|---|---|---|---|---|---|
| Male | Female | Male | Female | ||
| Age (y) | 53.2±11.8 | 51.6±12.7 | 55.2±14.1 | 53.2±12.2 | 0.381 |
| p | 0.753 | 0.5 | |||
| Comorbidity | |||||
| Yes (%) | 39.3 | 60.7 | 46.3 | 53.7 | 0.860 |
| No (%) | 50.0 | 50.0 | 68.4 | 31.6 | |
| p | 0.530 | 0.111 | |||
| VAS (3 mo) | 5±11.2 | 13.7±14.7 | 1.6±6.3 | 3.9±7.9 | 0.001 |
| p | 0.051 | 0.108 | |||
| HADS-anxiety (3 mo) | 4.4±5.5 | 4.3±4.4 | 1.4±2.4 | 1.5±2.7 | <0.001 |
| p | 0.761 | 0.653 | |||
| HADS-depression (3 mo) | 4.6±5.7 | 4±4.5 | 1.9±4.7 | 1.3±2.3 | <0.001 |
| p | >0.999 | 0.343 | |||
Data are presented as mean±standard deviation.
VAS, visual analog scale for measuring pain; HADS, hospital anxiety depression scale.
a)
Significance value of the parameters compared without male-female grouping between patients with and without severe fatigue at the third month.